Literature DB >> 1589858

Treatment of metastatic uveal melanoma: review and recommendations.

D M Albert1, A S Niffenegger, J K Willson.   

Abstract

This article reviews the published clinical responses of metastatic uveal melanoma and metastatic cutaneous melanoma with visceral involvement to current therapeutic protocols. Despite isolated patient responses to systemic treatment, no effective treatment currently exists for metastatic uveal melanoma. However, several new approaches involving interferons and interleukin and combination chemotherapy have shown some activity against metastatic cutaneous melanoma. The effectiveness against metastatic uveal melanomas has not been determined. A new approach to intrahepatic administration of chemotherapy also warrants further evaluation because of the high incidence of hepatic involvement with metastatic uveal melanoma. When an effective systemic treatment is found, early administration as an adjuvant to primary treatment may provide the best strategy for control of systemic spread.

Entities:  

Mesh:

Year:  1992        PMID: 1589858     DOI: 10.1016/s0039-6257(05)80024-4

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  18 in total

1.  Whole body PET/CT imaging for detection of metastatic choroidal melanoma.

Authors:  P T Finger; M Kurli; P Wesley; L Tena; K R Kerr; A Pavlick
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

2.  Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window.

Authors:  S R Boyd; D Tan; C Bunce; A Gittos; M H Neale; J L Hungerford; S Charnock-Jones; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

3.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

4.  c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma.

Authors:  J S Chana; G D Wilson; I A Cree; R A Alexander; N Myatt; M Neale; A J Foss; J L Hungerford
Journal:  Br J Ophthalmol       Date:  1999-01       Impact factor: 4.638

5.  Topical chemotherapy for conjunctival melanoma.

Authors:  P T Finger; M S Milner; S A McCormick
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

6.  Surgical resection plus biotherapy/chemotherapy improves survival of hepatic metastatic melanoma.

Authors:  Shun-Da Du; Yi-Lei Mao; Shao-Hua Li; Xin-Ting Sang; Xin Lu; Yi-Yao Xu; Hai-Feng Xu; Lin Zhao; Chun-Mei Bai; Shou-Xian Zhong; Jie-Fu Huang
Journal:  World J Hepatol       Date:  2012-11-27

7.  "Melanoma inhibitory activity" (MIA): a promising serological tumour marker in metastatic uveal melanoma.

Authors:  I W Reiniger; U C Schaller; C Haritoglou; R Hein; A K Bosserhoff; A Kampik; A J Mueller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-05-20       Impact factor: 3.117

8.  Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients.

Authors:  X Q Huang; M S Mitchell; P E Liggett; A L Murphree; J Kan-Mitchell
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

9.  Quality of evidence about effectiveness of treatments for metastatic uveal melanoma.

Authors:  James J Augsburger; Zélia M Corrêa; Adeel H Shaikh
Journal:  Trans Am Ophthalmol Soc       Date:  2008

10.  Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

Authors:  S C Edmunds; I A Cree; F Dí Nícolantonío; J L Hungerford; J S Hurren; D P Kelsell
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.